Pesquisas alternativas:
small compared » small companies (Expandir a Pesquisa), recall compared (Expandir a Pesquisa), small compound (Expandir a Pesquisa)
compared cases » compared case (Expandir a Pesquisa), collared cases (Expandir a Pesquisa), compares bases (Expandir a Pesquisa)
compared cause » compared case (Expandir a Pesquisa), complex cause (Expandir a Pesquisa), combined cause (Expandir a Pesquisa)
gel compared » model compared (Expandir a Pesquisa), level compared (Expandir a Pesquisa), tool compared (Expandir a Pesquisa)
cases non » causes non (Expandir a Pesquisa), case non (Expandir a Pesquisa), biases non (Expandir a Pesquisa)
cause new » causes new (Expandir a Pesquisa), use new (Expandir a Pesquisa), cause non (Expandir a Pesquisa)
j small » 1 small (Expandir a Pesquisa)
3 gel » _ gel (Expandir a Pesquisa), i gel (Expandir a Pesquisa), a gel (Expandir a Pesquisa)
small compared » small companies (Expandir a Pesquisa), recall compared (Expandir a Pesquisa), small compound (Expandir a Pesquisa)
compared cases » compared case (Expandir a Pesquisa), collared cases (Expandir a Pesquisa), compares bases (Expandir a Pesquisa)
compared cause » compared case (Expandir a Pesquisa), complex cause (Expandir a Pesquisa), combined cause (Expandir a Pesquisa)
gel compared » model compared (Expandir a Pesquisa), level compared (Expandir a Pesquisa), tool compared (Expandir a Pesquisa)
cases non » causes non (Expandir a Pesquisa), case non (Expandir a Pesquisa), biases non (Expandir a Pesquisa)
cause new » causes new (Expandir a Pesquisa), use new (Expandir a Pesquisa), cause non (Expandir a Pesquisa)
j small » 1 small (Expandir a Pesquisa)
3 gel » _ gel (Expandir a Pesquisa), i gel (Expandir a Pesquisa), a gel (Expandir a Pesquisa)
1
Publicado no Mol Cell Proteomics
(2017)
“... the small molecule is determined to cause a phenotypic alteration, follow-up work is necessary to decipher...”Obter o texto integral
Artigo
2
Publicado no Cell Prolif
(2002)
“...) and SPF (r = 0.77). P53 immunoreactivity was present in 71.4% of the tumours, whereas 39.3% of cases were...”Obter o texto integral
Obter o texto integral
Artigo
3
Publicado no Mol Cell Proteomics
(2019)
“... sensitivity despite ERBB2 amplification (pseudo-ERBB2+); 3) resistance features in true-ERBB2+ cases including...”Obter o texto integral
Artigo
4
Publicado no Mol Cell Proteomics
(2017)
“...3 Weimin Ni(1), Shou-Ling Xu(2), Eduardo González-Grandío(1), Robert J. Chalkley(3), Andreas F. R...”Obter o texto integral
Artigo
5
Publicado em 2014
“... small non-structural proteins (NS1 and NS2) which dampen the host cell innate immune system by targeting...”Obter o texto integral
Artigo
6
Publicado em 2009
“... Interactions T. Waldman(1), J. Kim(1), W. Lane(2), and F. Bunz(3,) (1)Georgetown Medical School/Lombardi Cancer...”Obter o texto integral
Obter o texto integral
Artigo
7
Publicado em 2009
“..., University of California, San Francisco, CA; (3)College of Life Sciences and Agriculture, University of New...”Obter o texto integral
Obter o texto integral
Artigo